login
  Password reminder
Vascular News
Contact the editor Visit Vascular News Twitter feed Visit Vascular News Facebook page
 

OSPREY trial completes US patient enrolment


Thursday, 12 Jul 2012 16:12
Misago
Misago

On 11 July, Terumo Interventional Systems announced the completion of US patient enrolment in the OSPREY (Occlusive/stenotic peripheral artery revascularization study) designed to evaluate the safety and effectiveness of the Misago Self-expanding Stent System. 


OSPREY is a single-arm, multicentre, non-randomised, prospective clinical trial for the treatment of atherosclerotic stenoses and occlusions of the superficial femoral artery that included 200 patients in 31 centres in the USA and 100 patients in seven centres in Japan.

A unique feature of this study is that it simultaneously enrolled patients in the USA and Japan as part of the larger Harmonization by Doing (HBD) pilot programme, a cooperative effort led by the FDA, the MHLW/PMDA (Japan’s regulatory body), Terumo Corporation, based in Tokyo, Japan, and Terumo Medical Corporation, based in Somerset, New Jersey, USA. The HBD initiative is intended to shorten the gap between product approvals in these two countries.


“Peripheral vascular disease is a leading cause of disability in the USA, affecting between 8 and 12 million Americans. It is critical that physicians, and their patients, have faster access to the latest technologies in order to maximise treatment options,” said J Fritz Angle, professor of Radiology, University of Virginia, and US principal investigator in the OSPREY trial. “I look forward to analysing and discussing the OSPREY data with all of the trial investigators. The international experience and testing efficiencies obtained from our collective participation in this HBD initiative could have a dramatic effect on the way important medical devices reach the market in the future.”


The MISAGO Self-expanding Stent consists of a nitinol stent pre-mounted on the distal portion of a rapid-exchange delivery catheter system. The stent has three radiopaque markers located on each end of the stent to help ensure accurate placement in the lesion. The stent is currently available for sale in Europe.

The first US patient implant in the OSPREY trial occurred in September 2010. The primary endpoints of the US arm of the OSPREY study are:

  • Primary stent patency rate at one year as confirmed by duplex ultrasound or angiography.
  • Freedom from major adverse events within 30 days of the procedure, which would result in target lesion revascularisation, amputation of the treated limb or death.

“OSPREY is Terumo Medical Corporation’s first US clinical trial for a premarket approval device and we are exceptionally pleased with its progress. Terumo is greatly appreciative of the tremendous support given by our US clinical investigators, which helped us meet the critical enrolment goal in this landmark HBD initiative,” said James Rushworth, president, Terumo Interventional Systems and Onset Medical Corporation. “The OSPREY trial and the MISAGO Stent truly speak to our three strategic pillars of introducing innovative technologies that create clinical, economic, and quality of life benefits.”




Add New Comment

Most popular


DEFINITIVE LE study results show directional atherectomy is safe and effective in claudication and critical limb ischaemia patients
Friday, 29 Aug 2014
The multicentre, 800-patient study also demonstrated that directional atherectomy was non-inferior for treating peripheral arterial disease in patients with diabetes compared with those without ... DEFINITIVE LE study results show directional atherectomy is safe and effective in claudication and critical limb ischaemia patients

Similar results with elective post-EVAR open conversion and primary open juxtarenal aneurysm repair for type Ia endoleak
Wednesday, 13 Aug 2014
Elective open surgical conversion for type Ia endoleak after endovascular aneurysm repair (EVAR) is not associated with increased morbidity or mortality compared with open juxtarenal aneurysm repair ... Similar results with elective post-EVAR open conversion and primary open juxtarenal aneurysm repair for type Ia endoleak

High patency rates with early cannulation graft with bioactive surface
Friday, 15 Aug 2014
Results of vascular access using a new ePTFE graft show “satisfactory” primary patency rates at one year, and are similar to those achieved with an autogenous access. In the experience, conducted in ... High patency rates with early cannulation graft with bioactive surface

Features


“Only operators and centres with the highest skill sets should be performing complex TEVAR”
Monday, 22 Sep 2014
With advances in technology, device availability and surgical skill sets we can expect the outcomes from endovascular repair of thoracoabdominal aortic aneurysms to continue to improve and become the ... “Only operators and centres with the highest skill sets should be performing complex TEVAR”

Eversion carotid endarterectomy: A technique that matters
Wednesday, 10 Sep 2014
Philip S K Paty, Albany, USA, says that eversion carotid endarterectomy is the preferred technique to treat carotid artery disease. Over the past two decades, his centre has performed over 11,000 of ... Eversion carotid endarterectomy: A technique that matters

Profiles


Cliff Shearman
Thursday, 03 Jul 2014
A former president of the Vascular Society of Great Britain and Ireland, Cliff Shearman was ... Cliff Shearman

Andrew Holden
Tuesday, 11 Feb 2014
Andrew Holden has been involved in the investigation of several endovascular devices for the ... Andrew Holden

Cardiac Rhythm News Vascular News Cardiovascular News Interventional News Spinal News NeuroNews
BIBA Medical BIBA MedTech Insights CX Symposium ilegx
 
Password Reminder

BIBA Medical, 526 Fulham Road, Fulham, London, SW6 5NR.
TEL: +44 (0)20 7736 8788 FAX: +44 (0)20 7736 8283 EMAIL: 
info@bibamedical.com
© BIBA Medical Ltd is a company registered in England and Wales with company number 2944429.
VAT registration number 730 6811 50.
Site Map | Terms and Conditions